Tcg Crossover Gp Ii, Llc Acquires 15,223 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc bought 15,223 shares of Surrozen stock in a transaction on Monday, March 23rd. The shares were acquired at an average cost of $24.90 per share, with a total value of $379,052.70. Following the completion of the acquisition, the insider owned 683,225 shares of the company’s stock, valued at $17,012,302.50. The trade was a 2.28% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Tuesday, March 24th, Tcg Crossover Gp Ii, Llc purchased 106,658 shares of Surrozen stock. The shares were acquired at an average price of $24.69 per share, for a total transaction of $2,633,386.02.
• On Monday, March 16th, Tcg Crossover Gp Ii, Llc acquired 1,190 shares of Surrozen stock. The shares were acquired at an average cost of $24.99 per share, with a total value of $29,738.10.
• On Friday, March 13th, Tcg Crossover Gp Ii, Llc acquired 35,433 shares of Surrozen stock. The stock was bought at an average price of $24.88 per share, with a total value of $881,573.04.
• On Thursday, March 12th, Tcg Crossover Gp Ii, Llc bought 12,374 shares of Surrozen stock. The stock was bought at an average cost of $24.99 per share, for a total transaction of $309,226.26.
• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc bought 1,093 shares of Surrozen stock. The stock was bought at an average cost of $23.86 per share, for a total transaction of $26,078.98.
• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc bought 17,763 shares of Surrozen stock. The shares were bought at an average price of $23.57 per share, for a total transaction of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc purchased 4,355 shares of Surrozen stock. The shares were bought at an average cost of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc purchased 731 shares of Surrozen stock. The stock was bought at an average price of $21.38 per share, with a total value of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The stock was bought at an average cost of $21.39 per share, for a total transaction of $91,356.69.

Surrozen Stock Up 7.1%

SRZN stock opened at $28.00 on Friday. The business’s 50-day moving average price is $24.50 and its 200-day moving average price is $18.87. The stock has a market cap of $239.96 million, a P/E ratio of -0.84 and a beta of 0.53. Surrozen, Inc. has a twelve month low of $5.90 and a twelve month high of $29.59.

Surrozen (NASDAQ:SRZN) last released its earnings results on Monday, March 23rd. The company reported ($7.59) EPS for the quarter, missing analysts’ consensus estimates of ($1.29) by ($6.30). Surrozen had a negative return on equity of 1,240.42% and a negative net margin of 7,476.67%.The firm had revenue of $0.53 million for the quarter, compared to the consensus estimate of $0.66 million. On average, equities research analysts expect that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

More Surrozen News

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Large insider buys by major shareholder TCG Crossover GP II — the fund bought 106,658 shares on March 24 (~$24.69 avg) and has repeatedly purchased stock in March, signaling strong insider conviction that can support the share price. SEC Filing
• Positive Sentiment: Additional TCG purchase: 15,223 shares on March 23 (~$24.90 avg), a follow-on buy that reinforces the insider buying narrative. InsiderTrades article
• Positive Sentiment: HC Wainwright reiterated a “Buy”, raised multi-quarter and multi-year EPS projections (less negative) and set a $36 price target — a constructive analyst view that can attract demand. Article
• Positive Sentiment: Cantor Fitzgerald assigned an “Overweight” rating with a higher price target (reported this week), providing another institutional buy-side signal. Article
• Neutral Sentiment: Institutional ownership is high (many hedge funds hold SRZN) and several institutions increased positions in recent quarters — supportive for liquidity but not an immediate catalyst.
• Negative Sentiment: Lifesci Capital cut multiple near-term EPS estimates (Q1–Q4 2026 and FY2026), making its outlook more pessimistic and creating downside pressure for sentiment. MarketBeat coverage
• Negative Sentiment: Recent quarterly results (reported March 23) were a significant miss (EPS deeply negative vs. expectations) and the company remains loss-making with volatile margins — a fundamental risk that keeps shares speculative despite positive headlines. Earnings detail

Hedge Funds Weigh In On Surrozen

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC increased its holdings in shares of Surrozen by 557.1% in the 4th quarter. Millennium Management LLC now owns 721,266 shares of the company’s stock worth $16,301,000 after buying an additional 611,497 shares during the last quarter. Stempoint Capital LP lifted its holdings in shares of Surrozen by 185.1% in the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after acquiring an additional 445,713 shares during the last quarter. Braidwell LP lifted its holdings in shares of Surrozen by 235.7% in the 4th quarter. Braidwell LP now owns 470,000 shares of the company’s stock valued at $10,622,000 after acquiring an additional 330,000 shares during the last quarter. Spruce Street Capital LP purchased a new position in Surrozen in the fourth quarter worth about $9,764,000. Finally, 5AM Venture Management LLC grew its position in Surrozen by 25.0% in the fourth quarter. 5AM Venture Management LLC now owns 387,500 shares of the company’s stock worth $8,758,000 after acquiring an additional 77,500 shares in the last quarter. Institutional investors own 66.57% of the company’s stock.

Wall Street Analyst Weigh In

SRZN has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. HC Wainwright reissued a “buy” rating and set a $36.00 price target (up from $32.00) on shares of Surrozen in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and issued a $40.00 price objective on shares of Surrozen in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Surrozen currently has an average rating of “Moderate Buy” and an average price target of $38.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.